Joris Pauty

Joris Pauty.jpg
Host Laboratory MATSUNAGA LAB.
Position in LIMMS  Postdoctoral Researcher
Main Research Topic in LIMMS

Bio-MEMS- Development of an on-a-chip tumor microenvironement model


Cancer, Tissue engineering, Tumor microenvironment, Tumor model, Vasculature model

Contact LIMMS/CNRS-IIS (UMI 2820)
Institute of Industrial Science, The University of Tokyo, 4-6-1 Komaba, Meguro-ku, Tokyo 153-8505, Japan
Phone:+81 (0)3 5452 6036 / Fax:+81 (0)3 5452 6088
E-mail j-pauty at


Short resume :

JSPS International Research Fellow at LiMMS (hosted in Dr Yukiko T. Matsunaga’s laboratory)


PhD program in Cellular and Molecular Biology at Faculty of Medicine of Laval University (hosted in Dr Jean-Yves Masson’s laboratory, Québec, Canada) 


Auditing Master of Science course in Molecular and Cellular Biology - Immunology at Université Pierre et Marie Curie (Paris, France)


Master of Science in Biotechnology (Diplôme d’Ingénieur), Institute of biotechnology IPB-ENSTBB (Bordeaux, France)

↑Page top

Research Projects in Limms

Development of an on-a-chip tumor microenvironment model

Context: In cancer research, a widely used model to study tumor growth and anti-tumor drugs/ therapies is the human tumor xenograft model. It consists in transplanting human cancer cells in immunodeficient mice. However, the tumor takes days to months to develop, when the graft does not fail. Moreover, although costly small animal imaging techniques can be used, this model is limited in the information that can be obtained regarding the interactions between the tumor and its environment. From another hand, the need for animal model alternatives is constantly increasing and is supported by the guiding principles known as the 3Rs (Replacement, Reduction, Refinement). Bio-MEMS that include engineered-tissues are one promising alternative.


Objectives & Methods: This project aims to develop a new in vitro tumor model that include the tumor microenvironment. The new model combines our previous vasculature-on-a-chip model (Fig.1) with cancer spheroids, which mimic tumors at a micrometer-scale (Fig.2). To get closer of in vivo conditions, the vasculature shall connect to a perfusion system in order to undergo shear stress.


Results:This new model will allow us to study tumor-driven angiogenesis [1] as well as the interactions between the cancer cells and the tumor microenvironment. It will also provide a tool for testing and developing candidate anticancer drugs.

[1] Jain, R.K. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med 7, 987-9 (2001).

↑Page top

Main publication List (papers, conferences and patent)



Couturier A, Fleury H, Patenaude AM, L. Bentley V, Rodrigue A, Coulombe Y, Niraj J, Pauty J, N. Berman J, Dellaire G, Di Noia J, Mes-Masson AM, Masson JY. Roles for APRIN (PDS5B) in homologous recombination and in ovarian cancer prediction. Nucleic Acids Research. 2016. In press.


Pauty J, Cote MF, Rodrigue A, Velic D, Masson JY, Fortin S. Investigation of the DNA damage response to SFOM-0046, a new small-molecule drug inducing DNA double-strand breaks. Scientific Reports. 2016;6:23302.



Pauty J, Rodrigue A, Couturier A, Buisson R, Masson JY. Exploring the roles of PALB2 at the crossroads of DNA repair and cancer. Biochemical Journal. 2014;460(3):331-42.

Buisson R, Niraj J, Pauty J, Maity R, Zhao W, Coulombe Y, et al. Breast cancer proteins PALB2 and BRCA2 stimulate polymerase eta in recombination-associated DNA synthesis at blocked replication forks. Cell Reports. 2014;6(3):553-64.


2013 and prior

Maity R*, Pauty J*, Krietsch J*, Buisson R, Genois MM, Masson JY. GST-His purification: a two-step affinity purification protocol yielding full-length purified proteins. Journal of Visualized Experiments. 2013(80):e50320. (*equal contribution) 

↑Page top